Sugi Predict

Sugi Predict / Compounds / SCHEMBL1199985

SCHEMBL1199985

SCHEMBL1199985

CCCC[C@@H](C)CCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.66
▸ ACE2 Q9BYF1 1/20 0.53
▸ AKR1B1 P15121 1/20 0.52
▸ GPR84 Q9NQS5 7/20 0.50
▸ PPARG P37231 7/20 0.50
▸ PPARD Q03181 7/20 0.50
▸ PPARA Q07869 7/20 0.50
▸ HDAC11 Q96DB2 5/20 0.50
▸ TSHR P16473 4/20 0.50
▸ PTPN1 P18031 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ TLR2 O60603 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ FABP4 P15090 2/20 0.50
▸ FFAR1 O14842 2/20 0.50
▸ FFAR4 Q5NUL3 2/20 0.50
▸ SLC22A6 Q4U2R8 1/20 0.50
▸ SLC22A8 Q8TCC7 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28308951 1.00 MAPT (0.66) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL13752139 1.00 MAPT (0.66) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL416333 1.00 MAPT (0.66) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL28861210 0.98 MAPT (0.64) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL31099430 0.98 MAPT (0.64) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL19065142 0.98 MAPT (0.64) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL2727702 0.98 MAPT (0.64) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL2803203 0.96 MAPT (0.62) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL12970771 0.96 MAPT (0.62) MAPTACE2AKR1B1GPR84PPARG
SCHEMBL3117112 0.93 MAPT (0.64) MAPTACE2AKR1B1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242624-A1 ALIPHATIC CYCLOPENTANONES AS MALODOR COUNTERACTING INGREDIENTS FIRMENICH SA (CH) 2025-11-27 — — WO disclosed
CN-117380269-B Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-04-05 — — CN disclosed
CN-111867396-B Salty and/or spicy taste enhancer 味之素株式会社 2024-01-19 — — CN disclosed
CN-117380269-A Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-01-12 — — CN disclosed
CN-110891615-B System and method for selecting and releasing fragrance 阿甘香气及精细化学有限公司 2022-08-05 — — CN disclosed
CN-111867396-A Salty and/or spicy taste enhancer 味之素株式会社 2020-10-30 — — CN disclosed
WO-2019177003-A1 SALTY TASTE- AND/OR SPICY TASTE-ENHANCING AGENT 味の素株式会社 2019-09-19 — — WO disclosed
CN-106999972-A System and method for discharging fragrance 阿甘芳香和精细化工有限公司 2017-08-01 — — CN disclosed
CN-106999973-A System and method for discharging edible material 阿甘芳香和精细化工有限公司 2017-08-01 — — CN disclosed
US-20140206670-A1 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS PFIZER INC. (US) 2014-07-24 — — US disclosed
US-20030195251-A1 Amino acids with affinity for the alpha-2-delta-protein BARTA NANCY SUE (US) 2003-10-16 — — US disclosed
WO-2003082807-A2 AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 — — WO disclosed
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids BELLIOTTI THOMAS RICHARD (US) 2003-09-25 — — US disclosed
US-20030176504-A1 Method of treating tinnitus DOOLEY DAVID JAMES (US) 2003-09-18 — — US disclosed
US-6620829-B2 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt WARNER-LAMBERT COMPANY 2003-09-16 — — US disclosed
WO-2003063845-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY LLC (US) 2003-08-07 — — WO disclosed
US-20020072533-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2002-06-13 — — US disclosed
EP-1199072-A2 Method of treating cartilage damage WARNER-LAMBERT COMPANY (US) 2002-04-24 — — EP disclosed
EP-1192125-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076958-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176504-A1 Method of treating tinnitus ADRA2A, ADRA1A, ADRA1D MAPT 3818/4885ACE2 2933/4885AKR1B1 660/4885
US-20020072533-A1 Method of treating cartilage damage COL2A1, COL1A1, GABRB1 MAPT 3900/4885ACE2 2874/4885AKR1B1 252/4885
US-20030195251-A1 Amino acids with affinity for the alpha-2-delta-protein SCN2A, OPRD1, CAMK2A MAPT 1240/4885ACE2 1053/4885AKR1B1 4387/4885
US-20140206670-A1 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS SLC6A2, OPRD1, ADRB2 MAPT 1524/4885ACE2 3555/4885AKR1B1 1394/4885
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids GABRB1, GABRA1, GABRB3 MAPT 1364/4885ACE2 4663/4885AKR1B1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.